Subtype and pathway specific responses to anticancer compounds in breast cancer. - Wikidata - wikimedia - TriplyDB

Subtype and pathway specific responses to anticancer compounds in breast cancer.

Subtype and pathway specific responses to anticancer compounds in breast cancer.

http://www.wikidata.org/entity/Q35779241

about

Cancer pharmacogenomics: strategies and challenges The Cancer Genome Atlas Pan-Cancer analysis project Pathway Analysis: State of the Art Leveraging big data to transform target selection and drug discovery Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics In vitro human cell line models to predict clinical response to anticancer drugs Toward precision medicine of breast cancer Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy Patient-derived tumour xenografts for breast cancer drug discovery HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer Cancer Genome Atlas Pan-cancer Analysis Project Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties High-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cells Widespread molecular patterns associated with drug sensitivity in breast cancer cell lines, with implications for human tumors Do breast cancer cell lines provide a relevant model of the patient tumor methylome?Conceptualizing cancer drugs as classifiers Context Sensitive Modeling of Cancer Drug Sensitivity Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action Pathway-Based Genomics Prediction using Generalized Elastic Net A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds Targeting the adaptability of heterogeneous aneuploids A community effort to assess and improve drug sensitivity prediction algorithms.Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.Computational solutions for omics data.Using large-scale molecular data sets to improve breast cancer treatment.Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivity Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser.Lean Big Data integration in systems biology and systems pharmacology.Disentangling multidimensional spatio-temporal data into their common and aberrant responses Publisher’s Note:Abstraction for data integration:Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction.dcVar: a method for identifying common variants that modulate differential correlation structures in gene expression data.Integrative "omic" analysis for tamoxifen sensitivity through cell based models.Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells.A personalized committee classification approach to improving prediction of breast cancer metastasis.Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

P2860

Q24289309-453721D1-9B6B-40F4-9EA0-958365514481 Q24606808-C56CA564-3F16-4DA7-A7FD-BA3E5FA4770B Q26770725-A38EB6BE-EA05-44FB-8988-37C108147F56 Q26776403-D2C08335-8B17-484C-961F-F845EF19AFE7 Q26801410-C9152CBA-E4DD-4889-8D50-B6DC06484FDA Q27000665-327180BD-C0F2-4ADA-9A10-B45FF4A82C29 Q28073967-931945E6-DE64-4A47-B90D-2907185A45CE Q28076097-2F8B2D01-EE17-4FAA-9992-AC575CA00928 Q28080046-040D1A91-5005-4623-9D74-914C39F70123 Q28085413-B83799FE-B3BC-4DAD-BAD5-189406FBD84C Q28085552-43079E7D-8120-4337-B02D-BCED8F0EFF5B Q28487333-0C201AF1-E2BF-4F66-BC3A-59FF0475644C Q28534624-F115E9DD-BA51-425A-A0BC-041A7CC0BF10 Q28538033-F2FD6949-DE1C-48F9-8CBD-E5704C10D757 Q28542556-BFB79E31-45A2-4DB6-AF97-C71A57037A18 Q28543160-1BBE13FC-8F08-4B97-A5F5-F9CAA752033E Q28547285-6579BD72-964C-4C8B-A67B-273013A02C79 Q28548411-B7DFAEAF-B34C-44E4-9AF0-18B3D73F48F1 Q28550614-1BD07100-2B97-474D-8BDE-3681F6663F67 Q28598343-AB973758-09DC-4A1B-9ECA-C9AC5A5F83FF Q28649939-0D1C715C-EE22-41BF-AC58-50225EF3250E Q30371323-575CF89B-8980-4370-8593-0D1B07AB6989 Q30436867-70A54FEE-083D-490C-B398-6ED1277BE9B6 Q30617899-364937EF-ACE8-4429-A6C5-4B7F06371D4F Q30656126-2526ADA8-255D-4948-B583-F019E30EA9D1 Q30664828-957BAC3F-3150-42F0-AF5B-7BAA215E40C4 Q30671000-E0D07A1D-7874-4F93-B377-2F528932575F Q30841748-5F5D1D87-8AB3-44D5-9C13-9F1D304DE1B8 Q30938497-4CC43967-AE67-4D36-A850-EA8B23EBBE17 Q30976077-C1B55EAE-D04C-4154-BD56-7FF23869AD69 Q31018233-8BDC15B1-D2E3-416E-A9E7-51C497953362 Q31156438-DBDF44A9-781D-441A-A23D-2B750A974CF3 Q33556468-1B2DA5D8-2043-49A5-9FED-90887276A476 Q33601653-1222D475-0521-4B94-9DB5-31555432F61A Q33605906-9AD34635-0ACD-426D-9A12-56A5AC5B3581 Q33623555-A5D7B037-D28E-4DCC-A73D-9C3E697FF3CE Q33731278-CB3C97EE-4548-4560-9208-CC65265780E4 Q33731365-386413DD-9BD6-4700-BECB-92396576B39D Q33807643-E3237D41-75DE-40C1-8C71-E4FB0344F2E4 Q33835127-2E569DF4-07F7-41A4-9537-4FD0DEC606E8

P2860

Subtype and pathway specific responses to anticancer compounds in breast cancer.

http://www.wikidata.org/entity/Q35779241

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Subtype and pathway specific responses to anticancer compounds in breast cancer.

@ast

Subtype and pathway specific responses to anticancer compounds in breast cancer.

@en

type

label

Subtype and pathway specific responses to anticancer compounds in breast cancer.

@ast

Subtype and pathway specific responses to anticancer compounds in breast cancer.

@en

prefLabel

Subtype and pathway specific responses to anticancer compounds in breast cancer.

@ast

Subtype and pathway specific responses to anticancer compounds in breast cancer.

@en

P1433

Q35779241-B3439B93-57F0-4751-8824-1CEB1A25D578

P1476

Q35779241-9453815A-4148-4AD7-9570-5092B97B3103

P2093

Q35779241-00A3A72B-078E-4CFC-AF37-F757786C784C

Q35779241-010D81A0-57E3-48FF-B7B0-A3580A65EB74

Q35779241-05B896AD-3358-48AF-93B9-CE83BD56AD20

Q35779241-07B0D7C5-BD77-4B6C-A56D-8B60A4EE6BFC

Q35779241-08233774-CD6D-4858-91FD-1D43CF619160

Q35779241-1560EE85-B71C-4231-A064-346261FF60E7

Q35779241-1B86C769-0AD5-4F91-BBA0-5D3660A3A7E9

Q35779241-206ECDDB-DBE6-4253-86A5-333CB7809C7D

Q35779241-22E2560A-FE73-4905-A5C0-077225423CBD

Q35779241-31B9A8C0-A1AA-49B8-A748-598454A44ADB

P2860

Q35779241-08019BD5-56CD-4E07-A14F-E4179CD8F7D6

Q35779241-0CAA19E6-63E5-433F-B731-2998F07C18CE

Q35779241-15E30D3C-C4E9-4290-85B1-A2F0D3719D01

Q35779241-2157B052-F664-4391-9BC4-93C65EF29298

Q35779241-22730A02-04C0-461B-AA02-B0AE0A4423E9

Q35779241-29979C25-1517-44E5-837F-46500D300FAA

Q35779241-2F08DD38-E8AE-44BD-A844-6E1288B50CD6

Q35779241-339DE04B-6C9F-4B65-A716-2BF8442C5C39

Q35779241-350BA1E1-9CD8-42B6-8FFB-8B7D5B01D5D7

Q35779241-3B0617F5-64E9-40AC-A6C6-F6D81D7D7238

P304

Q35779241-2D13B3B5-0136-43B3-B240-D8A1F6694282

P31

Q35779241-6ED1F196-4B7A-4AD7-9C6C-E3729FE13075

P356

Q35779241-C8A13A14-5BA1-4D24-9805-5B9849EBA19A

P407

Q35779241-E8BB83F3-DEEE-4EBF-AC9B-0C51997BD01B

P433

Q35779241-4873F9BD-D732-4236-8BB8-0B686778F08D

P478

Q35779241-D9942CE0-A803-46BC-B985-70B38FEE54AF

P50

Q35779241-21795011-8A0A-470C-9595-D01F9DBBA1DD

Q35779241-2D9CBEA4-8FF7-4D90-AB23-E9406AB6020C

Q35779241-8AAA2AFE-BC9F-4283-9948-3D1F31F1D03F

Q35779241-E5EB81FC-49E9-4088-9798-EEE100D5B18B

Q35779241-F7901501-98E3-42D3-A601-E3B81C1551E1

Q35779241-FE118644-2096-4FA7-BB84-57F8E51E8C2F

P577

Q35779241-46029A84-D5C2-4D11-8923-AF7ABA87F2B6

P5875

Q35779241-3463AE66-8205-4262-ADE7-F6E1920C9D5B

P698

Q35779241-7BCE1973-0834-4071-BB86-7BC1ADF854F6

P932

Q35779241-B91E0DDD-FBDF-4544-8D4B-3824163E8896

P356

PNAS.1018854108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Subtype and pathway specific responses to anticancer compounds in breast cancer.

@en

P2093

Andrea Dueregger

http://www.w3.org/2001/XMLSchema#string

Bryan T Hennessy

http://www.w3.org/2001/XMLSchema#string

Denise M Wolf

http://www.w3.org/2001/XMLSchema#string

Elizabeth Purdom

http://www.w3.org/2001/XMLSchema#string

Eric A Collisson

http://www.w3.org/2001/XMLSchema#string

Frances Tong

http://www.w3.org/2001/XMLSchema#string

François Pepin

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

Heidi S Feiler

http://www.w3.org/2001/XMLSchema#string

Henrik Bengtsson

http://www.w3.org/2001/XMLSchema#string

P2860

Significance analysis of microarrays applied to the ionizing radiation response

Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

Cisplatin: mode of cytotoxic action and molecular basis of resistance

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

P304

2724-2729

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1018854108

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

Anguraj Sadanandam

P577

2011-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51720091

http://www.w3.org/2001/XMLSchema#string

P698

22003129

http://www.w3.org/2001/XMLSchema#string

P932

3286973

http://www.w3.org/2001/XMLSchema#string